Chemomab Therapeutics (CMMB) Share-based Compensation Growth (1y) (2019 - 2023)
Chemomab Therapeutics (CMMB) Share-based Compensation Growth (1y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -40.86% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 109.70% |
| Sep 30, 2023 | -84.45% |
| Jun 30, 2023 | -16.03% |
| Mar 31, 2023 | -44.62% |
| Dec 31, 2022 | -268.47% |
| Sep 30, 2022 | 89.57% |
| Jun 30, 2022 | 44.40% |
| Mar 31, 2022 | 1,932.56% |
| Dec 31, 2021 | -589.71% |
| Sep 30, 2021 | 1,817.39% |
| Jun 30, 2021 | 1,782.14% |
| Mar 31, 2021 | -6.52% |
| Dec 31, 2020 | 52.81% |
| Sep 30, 2020 | -92.83% |
| Jun 30, 2020 | -92.39% |
| Mar 31, 2020 | -87.89% |
| Dec 31, 2019 | -75.55% |
| Sep 30, 2019 | 14.23% |